{"filing":{"accession_number":"0001628280-26-061208","cik":"0000805928","ticker":"AXGN","company_name":"Axogen, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-09","primary_document":"axgn-20260909.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/805928/000162828026061208/axgn-20260909.htm"},"events":[{"id":32467,"run_id":29831,"accession_number":"0001628280-26-061208","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Axogen entered into a definitive Agreement and Plan of Merger on September 9, 2026, to acquire BioCircuit Technologies for $200 million in cash, including BioCircuit's FDA-approved NerveTape product for peripheral nerve repair, with closing expected in Q4 2026.","company_name":"Axogen, Inc.","ticker":"AXGN","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35649,"accession_number":"0001628280-26-061208","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Axogen entered into a definitive Agreement and Plan of Merger on September 9, 2026, to acquire BioCircuit Technologies for $200 million in cash. This is a material acquisition disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The transaction involves the acquisition of BioCircuit's core business, including its FDA-approved NerveTape product for peripheral nerve repair, and is expected to close in Q4 2026. The filing explicitly describes this as a merger agreement with customary closing conditions and financing arrangements, making it a clear M\u0026A activity event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T10:07:41.900656+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35650,"accession_number":"0001628280-26-061208","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Axogen announced entry into a definitive merger agreement to acquire BioCircuit Technologies for $200 million in cash, with closing expected in Q4 2026. The press release (Exhibit 99.1) explicitly states \"Axogen, Inc. entered into a definitive agreement to acquire BioCircuit Technologies, Inc.\" This is a material acquisition that expands Axogen's product portfolio with NerveTape™, the first FDA-approved sutureless nerve repair device, and is expected to be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in the first year post-closing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T10:07:41.900656+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35649,"accession_number":"0001628280-26-061208","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Axogen entered into a definitive Agreement and Plan of Merger on September 9, 2026, to acquire BioCircuit Technologies for $200 million in cash. This is a material acquisition disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The transaction involves the acquisition of BioCircuit's core business, including its FDA-approved NerveTape product for peripheral nerve repair, and is expected to close in Q4 2026. The filing explicitly describes this as a merger agreement with customary closing conditions and financing arrangements, making it a clear M\u0026A activity event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T10:07:41.900656+00:00","company_name":"Axogen, Inc.","ticker":"AXGN","filing_date":"2026-09-10"},{"id":35650,"accession_number":"0001628280-26-061208","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Axogen announced entry into a definitive merger agreement to acquire BioCircuit Technologies for $200 million in cash, with closing expected in Q4 2026. The press release (Exhibit 99.1) explicitly states \"Axogen, Inc. entered into a definitive agreement to acquire BioCircuit Technologies, Inc.\" This is a material acquisition that expands Axogen's product portfolio with NerveTape™, the first FDA-approved sutureless nerve repair device, and is expected to be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in the first year post-closing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T10:07:41.900656+00:00","company_name":"Axogen, Inc.","ticker":"AXGN","filing_date":"2026-09-10"}]}